Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have received a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $29.00.
DAWN has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. Needham & Company LLC decreased their price objective on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th.
Check Out Our Latest Stock Report on DAWN
Insider Activity
Institutional Trading of Day One Biopharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the business. Virtus ETF Advisers LLC increased its holdings in shares of Day One Biopharmaceuticals by 7.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company’s stock worth $346,000 after acquiring an additional 1,805 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Day One Biopharmaceuticals by 5.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company’s stock valued at $454,000 after purchasing an additional 1,894 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. Exchange Traded Concepts LLC boosted its holdings in shares of Day One Biopharmaceuticals by 19.6% in the first quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company’s stock worth $117,000 after buying an additional 2,407 shares during the period. Finally, Optimize Financial Inc boosted its holdings in shares of Day One Biopharmaceuticals by 16.0% in the first quarter. Optimize Financial Inc now owns 17,960 shares of the company’s stock worth $142,000 after buying an additional 2,473 shares during the period. 87.95% of the stock is owned by institutional investors and hedge funds.
Day One Biopharmaceuticals Stock Up 2.7%
Shares of DAWN opened at $7.19 on Friday. Day One Biopharmaceuticals has a fifty-two week low of $6.08 and a fifty-two week high of $16.76. The firm’s 50 day moving average price is $6.64 and its 200 day moving average price is $8.87. The company has a market cap of $728.78 million, a P/E ratio of -10.13 and a beta of -1.27.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative return on equity of 14.98%. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. Research analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
- Five stocks we like better than Day One Biopharmaceuticals
- What is the Euro STOXX 50 Index?
- BigBear.ai: Why a 90% Rally Could Be Just the Start
- What is a Special Dividend?
- 5 Hot Stocks With Summer Buybacks You Can Cash In On
- What is the Dow Jones Industrial Average (DJIA)?
- Why Now Could Be the Smartest Time to Buy Crypto Stocks
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.